TARA vs. CSBR, BCLI, LJPC, IPHA, ZURA, ELEV, CHRS, CGEN, CMPX, and GLUE
Should you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include Champions Oncology (CSBR), Brainstorm Cell Therapeutics (BCLI), La Jolla Pharmaceutical (LJPC), Innate Pharma (IPHA), Zura Bio (ZURA), Elevation Oncology (ELEV), Coherus BioSciences (CHRS), Compugen (CGEN), Compass Therapeutics (CMPX), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "medical" sector.
Protara Therapeutics (NASDAQ:TARA) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, community ranking, earnings, profitability, risk, media sentiment and valuation.
Protara Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.
Champions Oncology has higher revenue and earnings than Protara Therapeutics. Champions Oncology is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Champions Oncology had 23 more articles in the media than Protara Therapeutics. MarketBeat recorded 28 mentions for Champions Oncology and 5 mentions for Protara Therapeutics. Champions Oncology's average media sentiment score of 1.04 beat Protara Therapeutics' score of 0.72 indicating that Champions Oncology is being referred to more favorably in the news media.
Protara Therapeutics currently has a consensus price target of $26.50, indicating a potential upside of 843.06%. Champions Oncology has a consensus price target of $7.50, indicating a potential upside of 65.56%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Protara Therapeutics is more favorable than Champions Oncology.
Champions Oncology received 118 more outperform votes than Protara Therapeutics when rated by MarketBeat users. However, 63.27% of users gave Protara Therapeutics an outperform vote while only 60.08% of users gave Champions Oncology an outperform vote.
38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 12.5% of Protara Therapeutics shares are owned by company insiders. Comparatively, 45.7% of Champions Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Protara Therapeutics has a net margin of 0.00% compared to Champions Oncology's net margin of -19.76%. Protara Therapeutics' return on equity of -58.80% beat Champions Oncology's return on equity.
Summary
Champions Oncology beats Protara Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Protara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protara Therapeutics Competitors List
Related Companies and Tools
